Is FDA-backed elastography poised to replace biopsy as the driver of MASH drug development?
Update: 2025-09-11
Description
The FDA has endorsed vibration-controlled transient elastography as a surrogate endpoint for MASH trials, marking the first non-invasive alternative to liver biopsy. A Japanese cohort study linked breakfast skipping and late dinners to higher fracture risk, with combined habits raising risk by nearly 25%. Finally, a global meta-analysis suggests shingles vaccination reduces major cardiovascular events by ~16–18%, though most evidence is observational.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
